` APLM (Apollomics Inc) vs S&P 500 Comparison - Alpha Spread

A
APLM
vs
S&P 500

Over the past 12 months, APLM has significantly outperformed S&P 500, delivering a return of +76% compared to the S&P 500's +15% growth.

Stocks Performance
APLM vs S&P 500

Loading
APLM
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
APLM vs S&P 500

Loading
APLM
S&P 500
Difference
www.alphaspread.com

Performance By Year
APLM vs S&P 500

Loading
APLM
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Apollomics Inc vs Peers

S&P 500
APLM
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Apollomics Inc
Glance View

Market Cap
18.4m USD
Industry
Biotechnology

Apollomics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Foster City, California. The company went IPO on 2021-11-26. The firm is focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics has a pipeline of approximately nine drug candidates across multiple programs, six of which are in the clinical-stage of development. Apollomics’ lead programs include investigating its core product, vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is in a Phase II multicohort clinical trial in the United States. The firm is also developing an anti-cancer enhancer drug candidate, uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers.

APLM Intrinsic Value
Not Available
A
Back to Top